UPINEMED

UpineMed is a clinical-stage biotechnology company based in Beijing, China, dedicated to the development of innovative adeno-associated virus (AAV) gene therapies. The company focuses on treating severe genetic and degenerative diseases, particularly in the fields of neurology, neuromuscular disorders, and ophthalmology. UpineMed leverages a proprietary AAV capsid evolution and engineering platform to create vectors with improved tissue specificity and reduced pre-existing immunity. Its lead candidate, UPM-01, is currently being evaluated in clinical trials for the treatment of Spinal Muscular Atrophy (SMA). The company is supported by prominent venture capital firms and aims to advance a robust pipeline of transformative genetic medicines to address high unmet medical needs.